Bortezomib Patent Expiration

1. Bortezomib patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572 FRESENIUS KABI USA Bortezomib formulations
Nov, 2032

(8 years from now)




Market Authorisation Date: 06 November, 2017

Treatment: NA

Dosage: POWDER

More Information on Dosage

BORTEZOMIB family patents

Family Patents

2. Bortezomib patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11679119 MAIA PHARMS INC Bortezomib compositions
Sep, 2042

(18 years from now)

US11752164 MAIA PHARMS INC Bortezomib compositions
Sep, 2042

(18 years from now)




Market Authorisation Date: 27 July, 2022

Treatment: Treatment of adult patients with multiple myeloma

Dosage: SOLUTION

More Information on Dosage

BORTEZOMIB family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Velcade patent expiration

VELCADE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6747150 TAKEDA PHARMS USA Boronic ester and acid compounds, synthesis and uses
Oct, 2014

(9 years ago)

US6617317 TAKEDA PHARMS USA Boronic ester and acid compositions
Oct, 2014

(9 years ago)

US6297217 TAKEDA PHARMS USA Boronic ester and acid compounds, synthesis and uses
Oct, 2014

(9 years ago)

US6083903 TAKEDA PHARMS USA Boronic ester and acid compounds, synthesis and uses
Oct, 2014

(9 years ago)

US7119080 TAKEDA PHARMS USA Boronic ester and acid compounds, synthesis and uses
Oct, 2014

(9 years ago)

US5780454 TAKEDA PHARMS USA Boronic ester and acid compounds
May, 2017

(7 years ago)

US5780454

(Pediatric)

TAKEDA PHARMS USA Boronic ester and acid compounds
Nov, 2017

(6 years ago)

US6958319 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(2 years ago)

US6713446 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(2 years ago)

US6713446

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(1 year, 11 months ago)

US6958319

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(1 year, 11 months ago)




Drug Exclusivity Drug Exclusivity Expiration
NR(NR) Jan 23, 2015
M(M-139) Aug 08, 2017
New Dosing Schedule(D-142) Oct 08, 2017
New Indication(I-695) Oct 08, 2017
New Dosing Schedule(D-141) Oct 08, 2017
M(M-165) Sep 14, 2018
Orphan Drug Exclusivity(ODE-76) Oct 08, 2021
Orphan Drug Exclusivity(ODE) Oct 08, 2021
Pediatric Exclusivity(PED) Apr 08, 2022

Market Authorisation Date: 13 May, 2003

Treatment: Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy

Dosage: INJECTABLE

How can I launch a generic of VELCADE before it's drug patent expiration?
More Information on Dosage

VELCADE family patents

Family Patents